Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 19 articles:
HTML format
Text format



Single Articles


    January 2019
  1. CAMPONE M, Bachelot T, Penault-Llorca F, Pallis A, et al
    A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Jan 25. pii: 10.1007/s00280-018-03765.
    PubMed     Text format     Abstract available


  2. NGUYEN TT, Angeli E, Darrouzain F, Nguyen QT, et al
    A successful compartmental approach for the treatment of breast cancer brain metastases.
    Cancer Chemother Pharmacol. 2019 Jan 5. pii: 10.1007/s00280-018-3752.
    PubMed     Text format     Abstract available


    November 2018
  3. CAZZANIGA ME, Ciruelos E, Fabi A, Garcia-Saenz J, et al
    Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.
    Cancer Chemother Pharmacol. 2018 Nov 20. pii: 10.1007/s00280-018-3717.
    PubMed     Text format     Abstract available


    October 2018
  4. ESIN E, Oksuzoglu B, Bilici A, Cicin I, et al
    Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes.
    Cancer Chemother Pharmacol. 2018 Oct 30. pii: 10.1007/s00280-018-3712.
    PubMed     Text format     Abstract available


  5. BAI Y, Wu HW, Zhang YH
    Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis.
    Cancer Chemother Pharmacol. 2018 Oct 24. pii: 10.1007/s00280-018-3703.
    PubMed     Text format     Abstract available


    July 2018
  6. HUANG W, Liu J, Zeng Y, Wu F, et al
    Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Cancer Chemother Pharmacol. 2018 Jul 24. pii: 10.1007/s00280-018-3639.
    PubMed     Text format     Abstract available


    June 2018
  7. XU C, Ravva P, Dang JS, Laurent J, et al
    A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
    Cancer Chemother Pharmacol. 2018 Jun 18. pii: 10.1007/s00280-018-3621.
    PubMed     Text format     Abstract available


  8. RODON J, Perez-Fidalgo A, Krop IE, Burris H, et al
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2018 Jun 7. pii: 10.1007/s00280-018-3610.
    PubMed     Text format     Abstract available


  9. IIZUMI S, Shimomura A, Shimoi T, Sudo K, et al
    Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.
    Cancer Chemother Pharmacol. 2018 Jun 5. pii: 10.1007/s00280-018-3617.
    PubMed     Text format     Abstract available


    May 2018
  10. HUANG JF, Wen CJ, Zhao GZ, Dai Y, et al
    Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3603.
    PubMed     Text format     Abstract available


  11. LEUNG HW, Ko CH, Yue GG, Herr I, et al
    The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3601.
    PubMed     Text format     Abstract available


  12. LITVIAKOV N, Tsyganov M, Larionova I, Ibragimova M, et al
    Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3594.
    PubMed     Text format     Abstract available


    March 2018
  13. KIMURA K, Iwamoto M, Tanaka S, Yamamoto D, et al
    A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3567.
    PubMed     Text format     Abstract available


    February 2018
  14. CITI V, Del Re M, Martelli A, Calderone V, et al
    Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Cancer Chemother Pharmacol. 2018 Feb 23. pii: 10.1007/s00280-018-3543.
    PubMed     Text format     Abstract available


  15. NAKAYAMA T, Sagara Y, Takashima T, Matsunami N, et al
    Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
    Cancer Chemother Pharmacol. 2018 Feb 21. pii: 10.1007/s00280-018-3544.
    PubMed     Text format     Abstract available


  16. LIU Z, Tao Z, Zhang Q, Wan S, et al
    YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 1. pii: 10.1007/s00280-018-3535.
    PubMed     Text format     Abstract available


    December 2017
  17. ZHOU X, Qiao G, Wang X, Song Q, et al
    CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
    Cancer Chemother Pharmacol. 2017 Dec 14. pii: 10.1007/s00280-017-3500.
    PubMed     Text format     Abstract available


  18. SHIEN T, Doihara H, Sato N, Anan K, et al
    Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
    Cancer Chemother Pharmacol. 2017 Dec 1. pii: 10.1007/s00280-017-3491.
    PubMed     Text format     Abstract available


    October 2017
  19. LI C, Wang B, Chen SC, Wada R, et al
    Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Cancer Chemother Pharmacol. 2017 Oct 11. doi: 10.1007/s00280-017-3440.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: